Background Image
Menu

Latest News

Abzena Says Gilead Advancing Antibody to Further Clinical Trials

19 May 2015

Abzena Says Gilead Advancing Antibody to Further Clinical Trials

Life sciences company Abzena PLC on Wednesday said US biotechnology company Gilead Sciences is to move the GS-5745 antibody directly into a phase 3 clinical study in gastic cancer in the third quarter of this year.

 The antibody uses Abzena's Composite Human Antibody technology. It is currently under evaluation for pancreatic cancer in a phase 1b study also and a phase 2 study for its use in Crohn's disease has also been initiated.

"We are encouraged by the clinical progress that Gilead is making with GS-5745 across a range of indications," said Abzena Chief Executive John Burt.